Related Experiment Video
Updated: Apr 10, 2026
06:07
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
6.3K
When Binding Is Not Blockade: Interpreting IgG4+ T Cells After PD-1 Therapy
Man Sun1, Dan Zang1, Jun Chen1
1Department of Oncology, The Second Hospital of Dalian Medical University, Dalian City, Liaoning Province, China.
Cancer Science
|April 9, 2026
Summary
Immunoglobulin G4 (IgG4) on T cells after PD-1 therapy may show antibody binding, not lasting blockade. Peripheral T-cell changes during ramucirumab, docetaxel, and G-CSF treatment are complex, limiting conclusions on antitumor immunity.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Programmed cell death protein 1 (PD-1) therapy is a cornerstone in cancer treatment.
- Assessing the efficacy of PD-1 blockade through peripheral biomarkers is crucial.
- Understanding T-cell dynamics during combination therapies is essential for optimizing treatment strategies.
Keywords:
IgG4‐positive T cellsPD‐1 blockadeantiangiogenic therapybiomarker interpretationimmunotherapy sequencing
